Recursion reported Q4 2025 financial results with $754 million in cash providing runway into early 2028. The company achieved clinical validation of its AI platform with REC-4881 showing meaningful polyp reductions in FAP patients and received its fifth Sanofi milestone payment. Full-year revenue reached $74.7 million while net loss widened to $644.8 million.
Autolus Therapeutics reported $74.3 million in 2025 revenue during its first commercial year, while facing a -265% gross margin. The company aims to achieve positive margins by 2026 through scaling production and expanding into autoimmune diseases with promising early lupus trial results. The broader CAR-T therapy market is projected to reach $9.85 billion in the US by 2033.
Metabolic pathway scores consistently distinguished patients who developed severe neurologic events after CAR T-cell therapy across six clinical trials, surpassing traditional inflammatory markers in predictive performance.
Phase 2 trial data show lisocabtagene maraleucel achieved a 95% overall response rate in patients with relapsed or refractory marginal zone lymphoma, with a manageable safety profile and no new safety signals.
FDA approves AstraZeneca's Calquence plus venetoclax as first all-oral, 14-month fixed-duration regimen for first-line chronic lymphocytic leukemia, with 77% of patients progression-free at three years in Phase III trial.
The FDA has approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration BTK inhibitor-based regimen for previously untreated adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
The FDA has accepted for filing the New Drug Application for tirabrutinib under the accelerated approval pathway for relapsed or refractory primary central nervous system lymphoma, setting a PDUFA action date of December 18, 2026.
CAR-T cell therapy engineering advances at Tandem 2026 focus on reducing toxicity and improving access, while McGill researchers develop targeted nanoparticle immunotherapy for lymph node metastases with fewer side effects.
Vertex Pharmaceuticals and CRISPR Therapeutics reported $116 million in full-year 2025 sales for gene-editing therapy Casgevy, with 64 patients receiving infusions and patient initiations nearly tripling compared to 2024.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07515313 |
Expression of CD274 (PD-L1) and CD276 in B-cell Malignancies: A Study by Flowcytometry |
NOT_YET_RECRUITING | |
| NCT07349849 |
Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies |
RECRUITING | EARLY_PHASE1 |
| NCT07271667 |
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies |
RECRUITING | PHASE2 |
| NCT07065279 |
JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies |
RECRUITING | NA |
| NCT06958679 |
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor |
RECRUITING | PHASE1 |
| NCT06542250 |
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. |
RECRUITING | PHASE1/PHASE2 |
| NCT05683717 |
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies |
RECRUITING | PHASE1 |
| NCT05275504 |
Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies |
UNKNOWN | PHASE1 |
| NCT04551963 |
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies |
COMPLETED | PHASE1 |
| NCT04509700 |
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) |
ACTIVE_NOT_RECRUITING | PHASE2 |
